The Pan-Immune-Inflammation Value is a new prognostic biomarker in metastatic colorectal cancer: results from a pooled-analysis of the Valentino and TRIBE first-line trialsGiovanni Fucà, Filippo Pietrantonio, Federica Marmorino et al.|British Journal of Cancer|2020Cited by 350
Upfront FOLFOXIRI plus bevacizumab with or without atezolizumab in the treatment of patients with metastatic colorectal cancer (AtezoTRIBE): a multicentre, open-label, randomised, controlled, phase 2 trialCarlotta Antoniotti, Chiara Cremolini, Daniele Rossini et al.|The Lancet Oncology|2022Cited by 268
Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite InstabilityBeatrice Borelli, Gianluca Masi|Cancers|2022Cited by 61